AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38328552
Drug: Part 1
RxNorm normalized name: INSULIN,ASPART 100 UNIT/ML 3ML CART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 therapy for 6 weeks followed by full therapy
Trial: 38328709
Drug: inetetamab (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inetetamab (loading dose of 8 mg/kg and subsequent doses of 6 mg/kg intravenously once every 3 weeks), pyrotinib (400 mg orally once daily), and vinorelbine (60 mg/m2 weekly)
Trial: 38328709
Drug: inetetamab, pyrotinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inetetamab, pyrotinib, and oral vinorelbine
Trial: 38329148
Drug: Tenecteplase (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase (0.25 mg/kg, up to 25 mg)
Trial: 38329153
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for 7 weeks
Trial: 38329404
Drug: Short-time cardiac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-time cardiac MRI in breast cancer participants undergoing chemotherapy
Trial: 38329404
Drug: Short-time cardiac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-time cardiac MRI in breast cancer participants undergoing immediate chemotherapy
Trial: 38329404
Drug: Short-time cardiac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-time cardiac MRI in breast cancer participants undergoing remote chemotherapy
Trial: 38329507
Drug: Adjuvant (super-)selective
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant (super-)selective infusion of holmium-166 microspheres after radiofrequency ablation
Trial: 38329646
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ocedurenone administered orally
Trial: 38329716
Drug: Futibatinib 20
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Futibatinib 20 mg once daily
Trial: 38329732
Drug: Paclitaxel treatment
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel treatment in breast cancer cohorts
Trial: 38329737
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy in combination with radiotherapy (IC-RT) group
Trial: 38329737
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy combined with chemoradiotherapy (IC-CCRT) group
Trial: 38330285
Drug: Apitegromab 20
RxNorm normalized name: Apitegromab
DrugBank: Apitegromab (DB16096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apitegromab 20 mg/kg alone or in combination with nusinersen (Cohort 1)
Trial: 38330285
Drug: Apitegromab 20
RxNorm normalized name: Apitegromab
DrugBank: Apitegromab (DB16096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apitegromab 20 mg/kg combined with nusinersen (Cohort 2)
Trial: 38330285
Drug: Apitegromab 2
RxNorm normalized name: Apitegromab
DrugBank: Apitegromab (DB16096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apitegromab 2 mg/kg combined with nusinersen (Cohort 3)
Trial: 38330285
Drug: Apitegromab 20
RxNorm normalized name: Apitegromab
DrugBank: Apitegromab (DB16096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apitegromab 20 mg/kg combined with nusinersen (Cohort 3)
Trial: 38330357
Drug: rCSP/GLA-LSQ 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rCSP/GLA-LSQ 10 µg × 3
Trial: 38330357
Drug: rCSP/GLA-LSQ 30 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rCSP/GLA-LSQ 30 µg × 3
Trial: 38330357
Drug: rCSP/GLA-LSQ 60 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rCSP/GLA-LSQ 60 µg × 3
Trial: 38330357
Drug: rCSP/GLA-LSQ 60 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rCSP/GLA-LSQ 60 µg × 2
Trial: 38330357
Drug: rCSP 30 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rCSP 30 µg alone × 3
Trial: 38330377
Drug: RKP00156 vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RKP00156 vaginal tablet (25 mg dose)
Trial: 38330377
Drug: RKP00156 vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RKP00156 vaginal tablet (10 mg or 50 mg doses)
Trial: 38330377
Drug: RKP00156 vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RKP00156 vaginal tablet
Trial: 38330380
Drug: Surgical debulking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical debulking of bulky or multiple lymph nodes before concurrent chemoradiation therapy (CCRT)
Trial: 38330409
Drug: Daily glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily glucose monitoring
Trial: 38330942
Drug: ADG106 (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADG106 (5.0 mg/kg dose level)
Trial: 38330942
Drug: ADG106 (10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADG106 (10.0 mg/kg dose level)
Trial: 38330975
Drug: Onradivir 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onradivir 200 mg twice per day
Trial: 38330975
Drug: Onradivir 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onradivir 400 mg twice per day
Trial: 38330975
Drug: Onradivir 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onradivir 600 mg once per day
Trial: 38330987
Drug: Survodutide 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survodutide 0.6 mg
Trial: 38847460
Drug: Survodutide 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survodutide 2.4 mg
Trial: 38330987
Drug: Survodutide 3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survodutide 3.6 mg
Trial: 38847460
Drug: Survodutide 4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survodutide 4.8 mg
Trial: 38331348
Drug: L-carnitine syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine syrup (100 mg/kg/d) for 15 days
Trial: 38332651
Drug: Pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment
Trial: 38332651
Drug: Fixed-dose hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose hydroxyurea
Trial: 38332651
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation hydroxyurea
Trial: 38332984
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) for 20 minutes at 2 mA for 10 daily sessions
Trial: 38333020
Drug: Callergin (iota-carrageenan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Callergin (iota-carrageenan nasal spray)
Trial: 38333967
Drug: ACLR+LEAP augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACLR+LEAP augmentation
Trial: 38334147
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (5 mg/m²)
Trial: 38334147
Drug: Methotrexate plus
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate plus intra-articular glucocorticoid (IAGC) therapy
Trial: 38334413
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine 0.1% solution
Trial: 38334470
Drug: Low-dose positron
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose positron emission mammography (PEM) with up to 185 MBq of fluorine 18-labeled fluorodeoxyglucose
Trial: 38335023
Drug: Wellinks intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wellinks intervention with remote health coaching, pulmonary rehabilitation, and group education; 6 coaching sessions in the first 12 weeks, followed by reduced frequency or discontinuation in the second 12 weeks.
Trial: 38335032
Drug: brepocitinib 45
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: brepocitinib 45 mg
Trial: 38335032
Drug: zimlovisertib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zimlovisertib 400 mg
Trial: 38335032
Drug: ropsacitinib 400
RxNorm normalized name: Ropsacitinib
DrugBank: Ropsacitinib (DB18709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropsacitinib 400 mg
Trial: 38335386
Drug: Integrative Korean
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Korean medicine treatment (herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, Chuna therapy, KM physiotherapy)
Trial: 38335474
Drug: Evobrutinib 75
RxNorm normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evobrutinib 75 mg BID
Trial: 38335474
Drug: Evobrutinib 25
RxNorm normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evobrutinib 25 mg QD
Trial: 38335474
Drug: Evobrutinib 75
RxNorm normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evobrutinib 75 mg QD
Trial: 38335474
Drug: Placebo (switched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (switched to evobrutinib 25 mg QD after week 24)
Trial: 38335474
Drug: Open-label dimethyl
RxNorm normalized name: Dimethyl sulfone
DrugBank: Dimethyl sulfone (DB14090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label dimethyl fumarate (DMF) 240 mg BID
Trial: 38335499
Drug: Vamorolone 6
RxNorm normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vamorolone 6 mg/kg/d
Trial: 38335499
Drug: Vamorolone 2
RxNorm normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vamorolone 2 mg/kg/d
Trial: 38335850
Drug: Palliative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Palliative radiotherapy (electron beam and photon beam therapies)
Trial: 38335978
Drug: Eltrombopag (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (150 mg, 100 mg for Asian patients) and cyclosporin A (10 mg/kg per day)
Trial: 38336731
Drug: PrEPare for
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEPare for Work Stage 2 intervention (1-on-1 skills training, problem-solving, and motivational interviewing adherence counseling and personalized, daily text message reminders)
Trial: 38336815
Drug: VagiBIOM suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VagiBIOM suppository
Trial: 38339248
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus 5-Azacitidine (3 mg/kg/dose)
Trial: 38340111
Drug: Esketamine treatment
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine treatment
Trial: 38340349
Drug: Immediate chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate chemotherapy (within 90 days after radium-223)
Trial: 38340349
Drug: Delayed chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed chemotherapy (more than 90 days after radium-223)
Trial: 38340349
Drug: Overall (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall (both immediate and delayed chemotherapy)
Trial: 38340677
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine 133 mg
Trial: 38340677
Drug: Bupivacaine hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine hydrochloride 50 mg
Trial: 38340723
Drug: Higher circulating
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher circulating MCPyV-specific CD8 T cell frequency before anti-PD-1 treatment
Trial: 38341525
Drug: Transversus thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transversus thoracic muscle plane block (TTMPB) with 20 ml of 0.25% bupivacaine on each side
Trial: 38341525
Drug: Pecto-intercostal fascial
RxNorm normalized name: Rompe Pecho
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pecto-intercostal fascial block (PIFB) with 20 ml of 0.25% bupivacaine on each side
Trial: 38342115
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg oral enobosarm daily
Trial: 38342115
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg oral enobosarm daily
Trial: 38342430
Drug: Neoadjuvant immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immunochemotherapy with adjuvant therapy
Trial: 38342441
Drug: Prednisone 40
RxNorm normalized name: prednisone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 40 mg orally for 30 days
Trial: 38342441
Drug: A+Z (anakinra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A+Z (anakinra 100 mg subcutaneously for 14 days plus zinc sulfate 220 mg orally for 90 days)
Trial: 38342735
Drug: Behavioral Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Activation (BA) intervention consisting of 10 weekly sessions including psychoeducation about depression, life areas and values assessment, activity scheduling, and self-monitoring of satisfaction and mood.
Trial: 38342735
Drug: Supportive Psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Psychotherapy (SP) as a standard of care control intervention consisting of 10 weekly sessions of reassurance, guidance, encouragement, and support.
Trial: 38343807
Drug: High-dose bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bolus of cholecalciferol (vitamin D)
Trial: 38344130
Drug: Scaling up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling up direct-acting antiviral (DAA) treatment in prisons by 44% for 10 years (2021-2030)
Trial: 38344130
Drug: Scaling up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling up HCV treatment excluding DAA pharmaceutical costs
Trial: 38344130
Drug: Scaling up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling up HCV testing and treatment in prisons
Trial: 38344130
Drug: Status quo
RxNorm normalized name: Statuss Green Reformulated Jan 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Status quo scenario (baseline levels of HCV treatment)
Trial: 38344178
Drug: 15 mg-tolvaptan
RxNorm normalized name: tolvaptan 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg-tolvaptan administered orally for 7 consecutive days
Trial: 38344232
Drug: Art-producing activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art-producing activities in a hybrid format (in-person and online) for 3 months on a weekly basis
Trial: 38344820
Drug: Insulin glargine,
RxNorm normalized name: insulin glargine, human recombin. analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin glargine, glimepiride, sitagliptin
Trial: 38344891
Drug: Buloxibutid (C21)
RxNorm normalized name: C18-C21 alkane
DrugBank: Buloxibutid (DB18038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buloxibutid (C21) intra-arterial infusion at doses of 3, 10, 30, 100, and 200 μg/min
Trial: 38344891
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) infusion at doses of 0.8-3.2 μg/min
Trial: 38345397
Drug: CB-011 (hypoimmunogenic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB-011 (hypoimmunogenic, allogeneic anti-BCMA CAR T cell therapy)
Trial: 38345463
Drug: Prehydrated collagenated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehydrated collagenated bone gel (test group; n=10)
Trial: 38345529
Drug: Belumosudil oral
RxNorm normalized name: belumosudil Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belumosudil oral suspension (200 mg)
Trial: 38345529
Drug: Belumosudil oral
RxNorm normalized name: belumosudil Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belumosudil oral suspension with food
Trial: 38345529
Drug: Belumosudil oral
RxNorm normalized name: belumosudil Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belumosudil oral suspension with sweetener/flavor vehicle
Trial: 38345529
Drug: Belumosudil oral
RxNorm normalized name: belumosudil Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belumosudil oral tablet (reference)
Trial: 38345710
Drug: SE-implant (slow-eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SE-implant (slow-eluting implant)
Trial: 38345710
Drug: FE-implant (fast-eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FE-implant (fast-eluting implant)
Trial: 38345710
Drug: SE-implant
RxNorm normalized name: selenomethionine Se 75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SE-implant
Trial: 38345710
Drug: FE-implant
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FE-implant
Trial: 38345718
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy compliance
Trial: 38345741
Drug: Optimized medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized medical treatment (OMT)
Trial: 38346237
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange treatment
Trial: 38346307
Drug: Collagenase Injection
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Collagenase Injection
Trial: 38347177
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor combined with albumin paclitaxel and apatinib
Trial: 38347552
Drug: Molecular tumor
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular tumor board (MTB) recommended combination therapy
Trial: 38347557
Drug: Routine administrative
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine administrative systems-level data on nursing care outcomes abstracted weekly.
Trial: 38347614
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron treatment
Trial: 38347736
Drug: Decompressive craniectomy
RxNorm normalized name: TUBE DECOMPRESSION BARD #000395
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decompressive craniectomy (DC) plus best medical treatment (BMT)
Trial: 38348238
Drug: macitentan 10
RxNorm normalized name: macitentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: macitentan 10 mg, with or without a phosphodiesterase 5 inhibitor (PDE5i)
Trial: 38348690
Drug: Zenocutuzumab, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zenocutuzumab, dosage and duration not specified
Trial: 38348827
Drug: Social interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Social interventions for support during treatment for endometrial cancer
Trial: 38349241
Drug: Real-time fMRI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time fMRI neurofeedback (15 weekly sessions)
Trial: 38349241
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) (10 weekly group sessions)
Trial: 38349333
Drug: 2 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 10^7 HXTCs/m² with VOR 400 mg
Trial: 38349371
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (single-dose treatment twice yearly for 3 years, 6 distributions)
Trial: 38349570
Drug: Feladilimab in
RxNorm normalized name: Feladilimab
DrugBank: Feladilimab (DB16415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feladilimab in combination with tremelimumab (24/225 mg)
Trial: 38349618
Drug: CT‑P41 (60-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT‑P41 (60-mg subcutaneous dose)
Trial: 38349618
Drug: US-denosumab (60-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-denosumab (60-mg subcutaneous dose)
Trial: 38349712
Drug: Comprehensive Care
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive Care Program (educational videos and follow-up visits by a family medicine physician)
Trial: 38349721
Drug: Web-based Culinary
RxNorm normalized name: Lens culinaris fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based Culinary Medicine intervention group (CMG) received weekly cooking demonstrations and biweekly nutrition education videos.
Trial: 38350047
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy after nephroureterectomy
Trial: 38350126
Drug: Subcutaneous catheter
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous catheter change